Core Insights - Scatec ASA has commenced commercial operations at the 273 MW Grootfontein solar power plant in South Africa, which is expected to generate predictable revenues through a 20-year power purchase agreement (PPA) [1][2] Company Overview - Scatec ASA is a leading renewable energy provider focused on delivering clean and reliable energy while creating long-term value for local communities and partners [2] - The company has a total of 6.2 GW of renewable energy capacity in operation and under construction across five continents [5] Project Details - The Grootfontein solar power plant is anticipated to generate 700 GWh of clean energy annually, resulting in an estimated reduction of 630,000 tonnes of CO2 emissions [4] - Scatec holds 51% equity in the project, with local partners H1 Holdings owning 46.5% and the Grootfontein Local Community Trust holding 2.5% [4] - The Grootfontein project is significant as it is Scatec's first project in the Western Cape and the first solar project to reach commercial operation under REIPPPP Round 5 [3]

Core Insights - Junshi Biosciences announced promising long-term survival results for toripalimab from the JUPITER-02 and JUPITER-06 trials at the ESMO ASIA Congress 2025, highlighting its potential as a leading immunotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and advanced esophageal squamous cell carcinoma (ESCC) [1][2] Group 1: JUPITER-02 Trial - JUPITER-02 is the first global multicenter, double-blind, randomized Phase 3 trial in immunotherapy for NPC, demonstrating significant long-term survival benefits with toripalimab plus chemotherapy [3][6] - The trial enrolled 289 chemotherapy-naïve patients with R/M NPC, showing a median overall survival (mOS) of 64.8 months for the toripalimab group compared to 33.7 months for the placebo group, representing a 39% reduction in death risk [5][8] - Toripalimab plus chemotherapy is now approved in over 40 countries and endorsed by major international guidelines, establishing a new standard of care for first-line treatment of R/M NPC [6][8] Group 2: JUPITER-06 Trial - JUPITER-06 is a Phase 3 trial evaluating toripalimab combined with paclitaxel and cisplatin (TP) chemotherapy for advanced or metastatic ESCC, showing a mOS of 17.7 months compared to 12.9 months for the placebo group, with a 28% reduction in death risk [11][12] - The trial included 514 systemic treatment-naïve patients, confirming consistent overall survival benefits across subgroups, regardless of PD-L1 expression status [12][14] - Toripalimab has gained approval for first-line treatment of advanced ESCC in multiple regions, including Europe, marking a significant milestone in immunotherapy [14][19] Group 3: Company Overview - Junshi Biosciences is an innovation-driven biopharmaceutical company focused on developing novel therapies, with a diverse R&D pipeline of over 50 drug candidates across various therapeutic areas [20][21] - The company has successfully developed toripalimab, China's first domestically produced anti-PD-1 monoclonal antibody, which has been approved in over 40 countries [20][21] - Junshi Biosciences aims to provide world-class, affordable, and innovative drugs, with a commitment to global health [21]

Core Insights - ORIC Pharmaceuticals announced promising data from a Phase 1b trial of enozertinib (ORIC-114) for treating NSCLC patients with EGFR exon 20 mutations, showing a 67% overall response rate (ORR) and 100% intracranial ORR in treatment-naïve patients with active brain metastases [1][2][16] - The drug demonstrated a 45% ORR in previously treated (2L) patients, surpassing competitor benchmarks, and exhibited a competitive safety profile with manageable on-target toxicity [1][4][5] - The company plans to continue enrollment and follow-up in 1L patients at a selected dose of 80 mg once daily, with the next update expected in mid-2026 ahead of a potential Phase 3 trial [1][12] Trial Design and Patient Demographics - The Phase 1b trial is evaluating enozertinib in patients with locally advanced or metastatic NSCLC with EGFR exon 20 mutations, allowing enrollment of patients with active untreated brain metastases [3] - As of August 29, 2025, 45 2L patients were dosed, with 38% having brain metastases at baseline [4] - In the 1L cohort, 33 patients were dosed, with 39% presenting with brain metastases [7] Safety and Efficacy Analysis - Preliminary safety analysis indicated that enozertinib was well tolerated, with most treatment-related adverse events (TRAEs) being Grade 1 or 2, and only a small number of patients discontinuing treatment due to TRAEs [5][9] - In the 80 mg cohort, 67% of responders remained on treatment at a median follow-up of over 30 weeks, while in the 120 mg cohort, 80% of patients underwent early dose reductions due to TRAEs [8][10][16] - The drug showed strong systemic and CNS antitumor activity, with 100% disease control rate (DCR) in patients with brain metastases [8][16] Next Steps and Future Plans - The company has selected 80 mg QD oral enozertinib as the dose for potential Phase 3 development, with ongoing enrollment and follow-up in 1L EGFR exon 20 patients [12] - A conference call and webcast is scheduled for December 6, 2025, to discuss the trial results and future plans [13]

Core Viewpoint - Copper Quest Exploration Inc. has successfully completed a non-brokered private placement, issuing 10,142,104 flow-through shares at a price of $0.19 per share, raising gross proceeds of $1,927,000 for exploration activities in British Columbia [1][2][3] Group 1: Private Placement Details - The private placement consists of flow-through shares, which will be utilized for Canadian exploration expenses and critical mineral mining expenditures [2] - The company paid cash finder's fees totaling $130,199.98 and issued 685,261 finder's warrants, allowing the holder to acquire one non-flow-through common share at an exercise price of C$0.19, expiring on December 5, 2027 [3] - The company may issue an additional 255,264 flow-through shares under the same terms by December 15, 2025, subject to a statutory hold period [5] Group 2: Company Strategy and Projects - The CEO of Copper Quest emphasized the company's focus on advancing its seven quality projects, including recent acquisitions, to enhance shareholder value through ground work and drilling in 2026 [3] - Copper Quest holds a 100% interest in several projects, including the Stars Property and the Nekash Copper-Gold Project, which are strategically located in key mining jurisdictions [10][11][12] - The company is committed to sustainable and responsible business practices, aiming to build shareholder value through project acquisition and development [14] Group 3: Industry Context - The copper market is facing persistent deficits due to rising global demand and challenges in new supply, highlighting the strategic importance of copper in the energy transition and modern infrastructure [9] - Recent U.S. policy changes, including import tariffs, underscore the need for resilient and localized resource exploration and development in the copper sector [9]

Core Viewpoint - HNI Corporation has announced a definitive agreement to acquire Steelcase, Inc. in a cash and stock transaction, with the acquisition expected to close on December 10, 2025 [1][4]. Group 1: Acquisition Details - The acquisition involves an exchange offer for Steelcase's existing 5.125% Notes due 2029, with HNI offering up to $450 million in new notes [1]. - Shareholders of both HNI and Steelcase voted in favor of the acquisition during their respective special meetings on December 5, 2025 [4]. - The acquisition is contingent upon the successful completion of the exchange offer and consent solicitation, which expired on December 5, 2025 [4][3]. Group 2: Exchange Offer and Consent Solicitation - HNI received sufficient consents to amend the Existing Steelcase Indenture to eliminate certain covenants and restrictive provisions [3]. - As of the expiration date, $351,008,000 of the Existing Steelcase Notes, representing 78% of the total, were validly tendered [6]. - The New HNI Notes will not be registered under the Securities Act and may only be offered under specific exemptions [7]. Group 3: Company Background - HNI Corporation has been in operation for over 75 years, focusing on workplace furnishings and residential building products [9]. - The Workplace Furnishings segment is a leading global designer and provider of commercial furnishings, while the Residential Building Products segment is the nation's leading manufacturer of hearth products [9].

New York, USA, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Webus International Limited (“Webus” or the “Company”) provides the following clarification regarding a press release on October 21, 2025, titled "Webus International Limited to Expand Wetour's Expedia TAAP Partnership with Integration of Expedia Group's Newly Announced AI Trip Planner and APIs." (the “Press Release”): The Press Release contains inaccurate descriptions of the scope of Webus’ relationship with Expedia Group, which Webus now seeks to clarify as ...

Company Leadership Change - Christopher Cherry will assume the role of Interim Chief Financial Officer, replacing David Worner, effective December 8, 2025 [1] - The company expresses gratitude to Mr. Worner for his contributions and wishes him well in future endeavors [1] Stock Options and Restricted Share Units - The company has granted a total of 579,028 stock options, exercisable at $0.84 per share, valid for a term of three to five years [2] - Additionally, 931,112 restricted share units have been issued, valid for a term between two to five years, to executive officers, directors, and consultants [2] - These stock options and restricted share units are part of the company's share compensation plans and are subject to vesting conditions [2] Company Overview - Rocket Doctor AI Inc. provides AI-powered healthcare solutions aimed at improving access to high-quality healthcare throughout the patient journey [3] - The company's technology includes the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from numerous physicians globally [3] Digital Health Platform - Rocket Doctor Inc. operates an AI-powered digital health platform and marketplace, enabling over 300 MDs to provide care for more than 700,000 patient visits [4] - The technology allows doctors to independently launch and manage virtual or hybrid in-person practices, enhancing efficiency and patient access [4] Commitment to Underserved Communities - The company aims to reduce administrative burdens and improve physician-patient interactions, particularly in underserved, rural, and remote communities in Canada [5] - It also supports patients on Medicaid and Medicare in the United States, focusing on making healthcare more scalable, equitable, and patient-centered [5]

Core Points - Skyharbour Resources Ltd. has successfully closed a non-brokered private placement financing, raising total gross proceeds of CAD $2,103,898.94, primarily from strategic institutional investors [1] - The funds will be allocated towards the company's 2026 exploration campaign, focusing on the Russell and Moore Lake Uranium Projects [1] - A total of 5,069,636 flow-through shares were issued at a price of CAD $0.415 per share, qualifying for a federal 30% Critical Mineral Exploration Tax Credit [2] - The company paid cash finder's fees of CAD $120,008.94 related to the private placement, which is pending final approval from the TSX Venture Exchange [3] - An insider director subscribed for 250,000 shares for gross proceeds of CAD $103,750, which is considered a related party transaction [4] Company Overview - Skyharbour holds a significant portfolio of uranium exploration projects in Canada's Athabasca Basin, covering over 616,000 hectares [6] - The company has acquired a 100% interest in the Moore Uranium Project, which is an advanced-stage property with high-grade uranium mineralization [6] - The Russell Lake Uranium Project, adjacent to Moore, also shows widespread uranium mineralization and exploration potential [6] - Skyharbour has joint ventures with industry leaders such as Denison Mines and Orano Canada Inc. at various projects [7] - The company has signed earn-in option agreements with partners that could lead to over CAD $76 million in partner-funded exploration expenditures [8] Strategic Goals - Skyharbour aims to maximize shareholder value through new mineral discoveries and long-term partnerships in favorable jurisdictions [9]

VANCOUVER, British Columbia, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Sable Resources Ltd. (“Sable” or the “Company”) (TSXV: SAE | OTCQB: SBLRF) is pleased to announce that the shareholders of the Company provided near unanimous approval of a new omnibus equity incentive plan (the “Equity Incentive Plan”) at the Company’s annual general and special meeting of shareholders held earlier today (the “Meeting”). All other matters advanced at the Meeting, including setting the board at five members, re-election of direc ...

NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Fly-E Group, Inc. (NASDAQ: FLYE, the “Company”), an electric vehicle company engaged in designing, installing, selling and renting smart electric motorcycles, electric bikes, and electric scooters, announced today that on November 25, the Company received a written notice (the “Notice”) from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it currently does not satisfy Listing Rule 5250(c)(1), as ...